Global pharmaceutical manufacturers are significantly increasing their industrial footprint in the United States as the incoming Trump administration weighs a 100% tariff on imported branded and patented medicines. To avoid these penalties, major industry players are fast-tracking domestic production facilities, stockpiling inventory, and negotiating direct agreements with the federal government.
Drugmakers Boost US Presence Amid Tariff Threats
Global drugmakers are boosting U.S. investments and stockpiling inventory to avoid 100% tariffs. Firms like Pfizer and Eli Lilly are expanding domestic plants.
Xurve View
洞察:
Xurve View











